Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

R. Younes; O. Govaere; S. Petta; Luca Miele; D. Tiniakos; A. Burt; E. David; F. M. Vecchio; M. Maggioni; D. Cabibi; A. L. Fracanzani; C. Rosso; M. J. G. Blanco; A. Armandi; G. P. Caviglia; M. Y. W. Zaki; A. Liguori; P. Francione; G. Pennisi; A. Grieco; L. Valenti; Q. M. Anstee; E. Bugianesi

doi:10.14309/ajg.0000000000000676

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

R. Younes
, O. Govaere
, S. Petta
, Luca Miele
, D. Tiniakos
, A. Burt
, E. David
, F. M. Vecchio
, M. Maggioni
, D. Cabibi
, A. L. Fracanzani
, C. Rosso
, M. J. G. Blanco
, A. Armandi
, G. P. Caviglia
, M. Y. W. Zaki
, A. Liguori
, P. Francione
, G. Pennisi
, A. Grieco

L. Valenti, Q. M. Anstee^*, E. Bugianesi^*

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

Lingua originale	Inglese
pagine (da-a)	1289-1292
Numero di pagine	4
Rivista	THE AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume	115
Numero di pubblicazione	8
DOI	https://doi.org/10.14309/ajg.0000000000000676
Stato di pubblicazione	Pubblicato - 2020

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

All Science Journal Classification (ASJC) codes

Epatologia
Gastroenterologia

Keywords

n/a

Accesso al documento

10.14309/ajg.0000000000000676

Altri file e collegamenti

Cita questo

Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., Fracanzani, A. L., Rosso, C., Blanco, M. J. G., Armandi, A., Caviglia, G. P., Zaki, M. Y. W., Liguori, A., Francione, P., Pennisi, G., ... Bugianesi, E. (2020). Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 115(8), 1289-1292. https://doi.org/10.14309/ajg.0000000000000676

@article{aa611e86ac4146de8997fe9ffe504073,

title = "Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease",

abstract = "INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9\% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.",

keywords = "n/a, n/a",

author = "R. Younes and O. Govaere and S. Petta and Luca Miele and D. Tiniakos and A. Burt and E. David and Vecchio, \{F. M.\} and M. Maggioni and D. Cabibi and Fracanzani, \{A. L.\} and C. Rosso and Blanco, \{M. J. G.\} and A. Armandi and Caviglia, \{G. P.\} and Zaki, \{M. Y. W.\} and A. Liguori and P. Francione and G. Pennisi and A. Grieco and L. Valenti and Anstee, \{Q. M.\} and E. Bugianesi",

year = "2020",

doi = "10.14309/ajg.0000000000000676",

language = "English",

volume = "115",

pages = "1289--1292",

journal = "THE AMERICAN JOURNAL OF GASTROENTEROLOGY",

issn = "1572-0241",

publisher = "New York: Elsevier Science",

number = "8",

}

Younes, R, Govaere, O, Petta, S, Miele, L, Tiniakos, D, Burt, A, David, E, Vecchio, FM, Maggioni, M, Cabibi, D, Fracanzani, AL, Rosso, C, Blanco, MJG, Armandi, A, Caviglia, GP, Zaki, MYW, Liguori, A, Francione, P, Pennisi, G, Grieco, A, Valenti, L, Anstee, QM & Bugianesi, E 2020, 'Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease', THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 115, n. 8, pagg. 1289-1292. https://doi.org/10.14309/ajg.0000000000000676

TY - JOUR

T1 - Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

AU - Younes, R.

AU - Govaere, O.

AU - Petta, S.

AU - Miele, Luca

AU - Tiniakos, D.

AU - Burt, A.

AU - David, E.

AU - Vecchio, F. M.

AU - Maggioni, M.

AU - Cabibi, D.

AU - Fracanzani, A. L.

AU - Rosso, C.

AU - Blanco, M. J. G.

AU - Armandi, A.

AU - Caviglia, G. P.

AU - Zaki, M. Y. W.

AU - Liguori, A.

AU - Francione, P.

AU - Pennisi, G.

AU - Grieco, A.

AU - Valenti, L.

AU - Anstee, Q. M.

AU - Bugianesi, E.

PY - 2020

Y1 - 2020

N2 - INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

AB - INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

KW - n/a

UR - https://publicatt.unicatt.it/handle/10807/219759

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85089206947&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85089206947&origin=inward

U2 - 10.14309/ajg.0000000000000676

DO - 10.14309/ajg.0000000000000676

M3 - Article

SN - 1572-0241

VL - 115

SP - 1289

EP - 1292

JO - THE AMERICAN JOURNAL OF GASTROENTEROLOGY

JF - THE AMERICAN JOURNAL OF GASTROENTEROLOGY

IS - 8

ER -

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Abstract

OSS delle Nazioni Unite

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo